Kliogest

Norethisterone acetate and estradiol, the active ingredients in Kliogest, are a combined oral contraceptive presented as an oral tablet for oral use. The formulation combines a progestogenic component with an estrogen component to achieve synergistic suppression of ovulation and stable endometrial changes. They are indicated for reliable contraception and for regulation of menstrual cycles in women of reproductive age.

GNH USA supplies Kliogest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance and regulatory conformity across multiple markets.

Kliogest, a combined oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy and normalize menstrual bleeding patterns. - Contraception: provides reliable prevention of pregnancy when taken as prescribed. - Menstrual cycle regulation: helps achieve more predictable and lighter menstrual bleeding. - Management of menstrual‑related symptoms: reduces dysmenorrhea and premenstrual mood swings.

Kliogest may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset often occurring early in treatment. - Breast tenderness: temporary discomfort or swelling of the breasts. - Headache: mild to moderate head pain. - Spotting or breakthrough bleeding: irregular light bleeding between periods. - Weight gain: slight increase in body weight. - Mood changes: irritability or emotional fluctuations.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Arterial thrombosis: clot formation in arteries leading to stroke or heart attack. - Hypertension: significant increase in blood pressure. - Liver dysfunction: abnormal liver enzyme elevations or jaundice. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Visual disturbances: sudden vision loss or blurred vision.

Before prescribing Kliogest, clinicians should evaluate several safety considerations. - Cardiovascular risk assessment: review history of thrombosis, hypertension, or smoking. - Liver function evaluation: avoid use in patients with active liver disease. - Smoking status: contraindicated in women over 35 who smoke. - Pregnancy testing: confirm non‑pregnant status prior to initiation. - Drug interaction review: assess concurrent use of enzyme‑inducing medications. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture.

Kliogest can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Rifampin and other strong CYP3A4 inducers: markedly reduce contraceptive efficacy. - St. John’s wort: herbal inducer that may decrease hormone levels. - Anticonvulsants such as carbamazepine or phenytoin: lower plasma concentrations of the active hormones.

Moderate Interactions (Monitor Closely): - Ketoconazole and other azole antifungals: may increase hormone levels and risk of side effects. - Efavirenz (antiretroviral): can modestly reduce contraceptive effectiveness. - NSAIDs: may increase risk of gastrointestinal bleeding when combined with estrogen. - Diuretics: may exacerbate blood pressure changes.